Conclusion of a non-exclusive discount agreement in accordance with Section 130a (8) SGB V for medicinal products with the active ingredient certolizumab pegol (ATC code: L04AB05) within the period from 1.6.2021 to 31.5.2023 with the option of concluding a contract at any time during the term (“open -house model ").

The contractual partners can be viewed at: https://www.aok-gesundheitpartner.de/nds/arzneimittel/rabatt/index_03504.html?bl=nds

The AOK - Die Gesundheitskasse für Niedersachsen intends, until exclusive contracts come into force after a public invitation to tender according to the regulations of the 4th part of the GWB, non-exclusive drug discount contracts for the active ingredient certolizumab pegol (ATC code: L04AB05) with as many market participants as possible (pharmaceutical companies or Communities of pharmaceutical companies) in the so-called "open-house model"

AOK Niedersachsen will not make a selection decision and will make an identical contract offer to every interested pharmaceutical company. In the open-house model, uniform conditions apply to all participants. The content of the contract, terms and conditions and access procedures are uniform - individual negotiations are generally not conducted. The contract terms are a maximum of twenty-four months, the earliest contract start is June 1st, 2021. All contracts end on May 31, 2023 at the latest, regardless of the date of the respective conclusion of the contract. Membership or the conclusion of a contract can take place within the twenty-four month period on the first of each month. There is a right of termination 6 weeks to the end of the month. AOK Niedersachsen reserves the right to replace the non-exclusive open-house discount agreements with exclusive discount agreements during the contract period. With the entry into force of advertised, exclusive discount contracts, the open-house contracts are terminated in accordance with the contractual regulation, ie the open-house contracts end automatically. According to the experience of AOK Lower Saxony, exclusive discount contracts usually come into effect 6 to 8 months after the publication of the corresponding announcement in the supplement to the Official Journal of the European Union. The future contractual partners in the open-house model are asked to regularly inform themselves about these tender announcements in the supplement to the Official Journal of the European Union.

Interested pharmaceutical companies can request the contractual documents and the contractual terms and conditions at the contact address given under I.1).

Contracts for the active ingredient certolizumab pegol will be concluded for the first time with effect from June 1, 2021. Interested parties who would like to become a contractual partner on this date must submit the contract documents to the address specified in the contract documents by April 27, 2021. It depends on the access at the AOK Lower Saxony. Later contracts are possible during the twenty-four month maximum term on the first of each month. Organizationally, a lead time of usually 35 calendar days on the part of the AOK is necessary in order to carry out the necessary work, e.g. B. to be able to guarantee the contract report in the Lauer-Taxe®. The exact deadlines for receipt will be announced with the contract documents. This publication does not concern the award of a public contract within the meaning of Directive (2014/24 / EU) or the GWB. In order to ensure the greatest possible degree of transparency for the intended conclusion of contracts, they are published in the supplement to the Official Journal of the European Union. In the absence of a corresponding publication form, the contract notice will be used. The resulting conceptual requirements, such as the process designation "open procedure", are solely due to the use of this announcement form and the publication platform. A further meaning, in particular a submission to subcontracting regulations, as far as they are not mandatory for legal reasons, is not associated with this.